Matthew Reynolds to Time Factors
This is a "connection" page, showing publications Matthew Reynolds has written about Time Factors.
Connection Strength
1.254
-
Zeitler EP, Bian B, Griffiths RI, Allocco DJ, Christen T, Roy K, Cohen DJ, Reynolds MR. Long-Term Clinical Outcomes Following the WATCHMAN Device Use in Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2024 Oct; 17(10):e011007.
Score: 0.131
-
Griffiths RI, Amorosi SL, Jacobsen CM, McBee PJ, Menzin J, Reynolds MR. Costs and complications associated with transvenous lead reoperation in cardiac implantable electronic devices. J Cardiovasc Electrophysiol. 2020 02; 31(2):503-511.
Score: 0.095
-
Reynolds MR, Zheng Q, Doros G. Laser balloon ablation for AF: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2018 10; 29(10):1363-1370.
Score: 0.086
-
Kramer DB, Jones PW, Rogers T, Mitchell SL, Reynolds MR. Patterns of physical activity and survival following cardiac resynchronization therapy implantation: the ALTITUDE activity study. Europace. 2017 Nov 01; 19(11):1841-1847.
Score: 0.081
-
Turakhia MP, Zweibel S, Swain AL, Mollenkopf SA, Reynolds MR. Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks. Circ Cardiovasc Qual Outcomes. 2017 02; 10(2).
Score: 0.077
-
Chyou JY, Hunter TD, Mollenkopf SA, Turakhia MP, Reynolds MR. Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. J Am Heart Assoc. 2015 Jul 23; 4(7).
Score: 0.069
-
Kramer DB, Mitchell SL, Monteiro J, Jones PW, Normand SL, Hayes DL, Reynolds MR. Patient Activity and Survival Following Implantable Cardioverter-Defibrillator Implantation: The ALTITUDE Activity Study. J Am Heart Assoc. 2015 May 15; 4(5).
Score: 0.069
-
Reynolds MR, Apruzzese P, Galper BZ, Murphy TP, Hirsch AT, Cutlip DE, Mohler ER, Regensteiner JG, Cohen DJ. Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial. J Am Heart Assoc. 2014 Nov 11; 3(6):e001233.
Score: 0.066
-
Reynolds MR, Lin J, Jhaveri M, Mozaffari E, Plich A. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Am J Ther. 2014 Nov-Dec; 21(6):500-8.
Score: 0.066
-
Ladapo JA, David G, Gunnarsson CL, Hao SC, White SA, March JL, Reynolds MR. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation. J Cardiovasc Electrophysiol. 2012 Jan; 23(1):1-8.
Score: 0.053
-
Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006 Dec; 152(6):1097-103.
Score: 0.038
-
Reynolds MR, Joventino LP, Josephson ME. Relationship of baseline electrocardiographic characteristics with the response to cardiac resynchronization therapy for heart failure. Pacing Clin Electrophysiol. 2004 Nov; 27(11):1513-8.
Score: 0.033
-
Witte KK, Tsivgoulis G, Reynolds MR, Tsintzos SI, Eggington S, Ismyrloglou E, Lyon J, Huynh M, Egea M, de Brouwer B, Ziegler PD, Franco N, Joglekar R, Rosemas SC, Liu S, Thijs V. Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. BMC Cardiovasc Disord. 2021 03 31; 21(1):160.
Score: 0.026
-
Resnic FS, Majithia A, Dhruva SS, Ssemaganda H, Robbins S, Marinac-Dabic D, Hewitt K, Ohno-Machado L, Reynolds MR, Matheny ME. Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures. Circ Cardiovasc Qual Outcomes. 2020 04; 13(4):e006105.
Score: 0.024
-
Field ME, Gold MR, Reynolds MR, Goldstein L, Lee SHY, Kalsekar I, Coplan P, Wong C, Khanna R, Winterfield JR. Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
Score: 0.024
-
Culler SD, Kugelmass AD, Cohen DJ, Reynolds MR, Katz MR, Brown PP, Schlosser ML, Simon AW. Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period of an Acute Myocardial Infarction Admission. J Am Heart Assoc. 2019 11 05; 8(21):e013513.
Score: 0.023
-
Galper BZ, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, Yeh RW. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
Score: 0.023
-
Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MJ, Brown DL, Russo MJ, Smith CR, Webb J, Miller C, Leon MB, Cohen DJ. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019 02 12; 139(7):877-888.
Score: 0.022
-
Arnold SV, Li Z, Vemulapalli S, Baron SJ, Mack MJ, Kosinski AS, Reynolds MR, Hermiller JB, Rumsfeld JS, Cohen DJ. Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year: Analysis of the Transcatheter Valve Therapy Registry. JAMA Cardiol. 2018 12 01; 3(12):1151-1159.
Score: 0.022
-
Kramer DB, Habtemariam D, Adjei-Poku Y, Samuel M, Engorn D, Reynolds MR, Mitchell SL. The Decisions, Interventions, and Goals in ImplaNtable Cardioverter-DefIbrillator TherapY (DIGNITY) Pilot Study. J Am Heart Assoc. 2017 Sep 22; 6(9).
Score: 0.020
-
Baron SJ, Arnold SV, Reynolds MR, Wang K, Deeb M, Reardon MJ, Hermiller J, Yakubov SJ, Adams DH, Popma JJ, Cohen DJ. Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. Am Heart J. 2017 Dec; 194:39-48.
Score: 0.020
-
Chun KRJ, Brugada J, Elvan A, Gell?r L, Busch M, Barrera A, Schilling RJ, Reynolds MR, Hokanson RB, Holbrook R, Brown B, Schl?ter M, Kuck KH. The Impact of Cryoballoon Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation on Healthcare Utilization and Costs: An Economic Analysis From the FIRE AND ICE Trial. J Am Heart Assoc. 2017 Jul 27; 6(8).
Score: 0.020
-
Calnan DR, D'Agostino E, Reynolds MR, Bekelis K. Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions. Curr Pharm Des. 2017; 23(42):6399-6410.
Score: 0.019
-
Arnold SV, Reynolds MR, Wang K, Magnuson EA, Baron SJ, Chinnakondepalli KM, Reardon MJ, Tadros PN, Zorn GL, Maini B, Mumtaz MA, Brown JM, Kipperman RM, Adams DH, Popma JJ, Cohen DJ. Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk: Results From the CoreValve US Pivotal Trial. JACC Cardiovasc Interv. 2015 Aug 17; 8(9):1207-1217.
Score: 0.017
-
Pinto DS, Kohli P, Fan W, Kirtane AJ, Kociol RD, Meduri C, Deliargyris EN, Prats J, Reynolds MR, Stone GW, Michael Gibson C. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. Catheter Cardiovasc Interv. 2016 Feb 15; 87(3):363-73.
Score: 0.017
-
Murphy RK, Liu B, Srinath A, Reynolds MR, Liu J, Craighead MC, Camins BC, Dhar R, Kummer TT, Zipfel GJ. No additional protection against ventriculitis with prolonged systemic antibiotic prophylaxis for patients treated with antibiotic-coated external ventricular drains. J Neurosurg. 2015 May; 122(5):1120-6.
Score: 0.017
-
Arnold SV, Lei Y, Reynolds MR, Magnuson EA, Suri RM, Tuzcu EM, Petersen JL, Douglas PS, Svensson LG, Gada H, Thourani VH, Kodali SK, Mack MJ, Leon MB, Cohen DJ. Costs of periprocedural complications in patients treated with transcatheter aortic valve replacement: results from the Placement of Aortic Transcatheter Valve trial. Circ Cardiovasc Interv. 2014 Dec; 7(6):829-36.
Score: 0.016
-
Lim DS, Reynolds MR, Feldman T, Kar S, Herrmann HC, Wang A, Whitlow PL, Gray WA, Grayburn P, Mack MJ, Glower DD. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014 Jul 15; 64(2):182-92.
Score: 0.015
-
Kramer DB, Kennedy KF, Noseworthy PA, Buxton AE, Josephson ME, Normand SL, Spertus JA, Zimetbaum PJ, Reynolds MR, Mitchell SL. Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):488-97.
Score: 0.015
-
Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y, Beachy J, Blum Meisnere L, Conyers del M, Reynolds MR, Heidenreich PA, Al-Khatib SM, Pina IL, Blake K, Norine Walsh M, Wilkoff BL, Shalaby A, Masoudi FA, Rumsfeld J. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013 Apr; 10(4):e59-65.
Score: 0.015
-
Abdelhadi RH, Saba SF, Ellis CR, Mason PK, Kramer DB, Friedman PA, Gura MT, DiMarco JP, Mugglin AS, Reynolds MR, Bazaz RR, Retel LK, Hayes DL, Hauser RG. Independent multicenter study of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm. 2013 Mar; 10(3):361-5.
Score: 0.014
-
Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008 Nov 25; 52(22):1758-68.
Score: 0.011
-
Zimetbaum P, Reynolds MR, Ho KK, Gaziano T, McDonald MJ, McClennen S, Berezin R, Josephson ME, Cohen DJ. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol. 2003 Sep 15; 92(6):677-81.
Score: 0.008